Bergenbio Aktie (A2DPC0 | 7BG

Was macht Bergenbio?

Unternehmensprofil

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.

Chart der Bergenbio Aktie

Charttool öffnen

Aktuelle Nachrichten zu Bergenbio

Weitere Nachrichten

Das berichten andere über Bergenbio

BerGenBio ASA – Updated key information related to the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLES REPUBLIC...

BerGenBio ASA: Update on Strategic Review Process and Status of Activities

Bergen, 3 June 2025 – Reference is made to previous stock exchange announcements from BerGenBio ASA ("BerGenBio" or the "Company") dated 25 February 2025 and 17 March 2025...

BerGenBio announces advancement of its strategic review

Bergen, Norway, March 17, 2025 – Reference is made to the stock exchange announcement on 25 February 2025 from BerGenBio ASA (OSE: BGBIO) (the "Company"), a clinical-stage...

BerGenBio ASA: Minutes from Extraordinary General Meeting

Bergen, Norway,10 October 2024 – An Extraordinary general meeting of BerGenBio ASA was virtually held today 10 October 2024 at 10.00 CEST. All proposals were resolved...